- TételKorlátozottan hozzáférhető
- TételKorlátozottan hozzáférhető
- TételKorlátozottan hozzáférhetőThe use of targeted therapy in gastric cancerThesis on the use of targeted therapy in gastric cancer. Gastric cancer is the fifth most common cancer globally and a leading cause of cancer-related deaths. Despite the high incidence, there has been limited molecular focus on this cancer type until recently Biomarkers and Diagnostic Testing Efforts are being made to individualize treatment through biomarker testing. Liquid biopsies and tests for HER2 overexpression, PD-L1, and MSI or MMR are becoming increasingly important in treatment decisions. Pathophysiology and Risk Factors The development of gastric cancer is influenced by a combination of genetic and environmental factors, including H. pylori infection. Interestingly, there may be distinct risk factors for tumors developing in different regions of the stomach. Advancements in Treatment: The Role of Targeted Therapy In the treatment landscape, the advent of targeted therapies like trastuzumab and ramucirumab has shown promise in improving overall survival rates. These therapies are especially effective for specific molecular subtypes of the disease and come with fewer side effects compared to traditional chemotherapy. Clinical Implications and Future Directions While surgery remains the cornerstone of curative treatment, the incorporation of targeted therapies offers a more effective and less toxic treatment approach for specific patient populations. Future research should focus on validating these molecular classifications and expanding the range of targeted therapies available. Conclusion In summary, as our understanding of the molecular underpinnings of gastric cancer deepens, targeted therapy is emerging as a pivotal player in the management of this devastating disease. Thank you for your attention, and I am open to any questions you may have.
- TételKorlátozottan hozzáférhetőContemporary Diagnosis of Pediatric non-CML Myeloproliferative NeoplasmsIn this study, our aim was to evaluate the laboratory findings of pediatric patients with Polycythemia Vera (PV), and Essential Thrombocythemia (ET). For this, bone marrow and peripheral blood samples were collected from eight patients. Mononuclear cells were isolated and counted, then, to analyze cells, colony Forming Cell (CFC) assay was performed and colonies were counted and identified. We performed 14 CFC assays for eight cases. Colonies grew successfully for three patients and did not grow from the remaining five patients. In conclusion, analysis of cell types by CFC can aid in the confirmation of diagnosis of pediatric Ph-negative MPN even in the absence of known driver mutations.
- TételKorlátozottan hozzáférhetőCELL DIFFERENTIATION FROM BONE MARROW DERIVED STEM CELLSThe function of dendritic cells (DCs) is to process antigen material and present it to T lymphocytes, initiating the adaptive immune response. DCs can be used in cell therapy to treat tumors or autoimmune diseases thus, they are an aspect when it comes to immunotherapy. In this study we tried to generate bone marrow derived DC (BM-DCs) and the major goal was to test various cytokines to get functional immune cells from adult stem cells. To produce BM-DCs, isolated mouse bone marrow cells were ex vivo differentiated for 9 days. The differentiated cells were cultured in the RPMI medium in the presence of GM-CSF, with or without IL-4 and/or Flt3L. Finally, LPS was added at day 8 to induce maturation and the obtained BM-DCs were harvested at day 9. We carried out multicolor flow cytometric analysis at day 9 to assess the expression of several DC and maturation specific proteins in BM-DCs. Our data revealed that GM-CSF combined with IL-4 leads to the formation of more activated BMDCs which are exhibited an elevated expression of MHC II, CD86, and CD40, especially, in the presence of LPS activation. In addition, our data suggest that high concentration of Flt3L modifies the phenotype of the GM-CSF instructed BM-DCs.